451 related articles for article (PubMed ID: 28192788)
1. Metabolic gatekeeper function of B-lymphoid transcription factors.
Chan LN; Chen Z; Braas D; Lee JW; Xiao G; Geng H; Cosgun KN; Hurtz C; Shojaee S; Cazzaniga V; Schjerven H; Ernst T; Hochhaus A; Kornblau SM; Konopleva M; Pufall MA; Cazzaniga G; Liu GJ; Milne TA; Koeffler HP; Ross TS; Sánchez-García I; Borkhardt A; Yamamoto KR; Dickins RA; Graeber TG; Müschen M
Nature; 2017 Feb; 542(7642):479-483. PubMed ID: 28192788
[TBL] [Abstract][Full Text] [Related]
2. Loss of Pax5 Exploits Sca1-BCR-ABL
Martín-Lorenzo A; Auer F; Chan LN; García-Ramírez I; González-Herrero I; Rodríguez-Hernández G; Bartenhagen C; Dugas M; Gombert M; Ginzel S; Blanco O; Orfao A; Alonso-López D; Rivas JL; García-Cenador MB; García-Criado FJ; Müschen M; Sánchez-García I; Borkhardt A; Vicente-Dueñas C; Hauer J
Cancer Res; 2018 May; 78(10):2669-2679. PubMed ID: 29490943
[TBL] [Abstract][Full Text] [Related]
3. EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
Somasundaram R; Jensen CT; Tingvall-Gustafsson J; Åhsberg J; Okuyama K; Prasad M; Hagman JR; Wang X; Soneji S; Strid T; Ungerbäck J; Sigvardsson M
Blood; 2021 Jun; 137(22):3037-3049. PubMed ID: 33619557
[TBL] [Abstract][Full Text] [Related]
4. B-cell identity as a metabolic barrier against malignant transformation.
Chan LN; Müschen M
Exp Hematol; 2017 Sep; 53():1-6. PubMed ID: 28655536
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
6. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.
Pan L; Hong C; Chan LN; Xiao G; Malvi P; Robinson ME; Geng H; Reddy ST; Lee J; Khairnar V; Cosgun KN; Xu L; Kume K; Sadras T; Wang S; Wajapeyee N; Müschen M
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33531346
[TBL] [Abstract][Full Text] [Related]
7. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Mullighan CG; Su X; Zhang J; Radtke I; Phillips LA; Miller CB; Ma J; Liu W; Cheng C; Schulman BA; Harvey RC; Chen IM; Clifford RJ; Carroll WL; Reaman G; Bowman WP; Devidas M; Gerhard DS; Yang W; Relling MV; Shurtleff SA; Campana D; Borowitz MJ; Pui CH; Smith M; Hunger SP; Willman CL; Downing JR;
N Engl J Med; 2009 Jan; 360(5):470-80. PubMed ID: 19129520
[TBL] [Abstract][Full Text] [Related]
8. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.
Xiao G; Chan LN; Klemm L; Braas D; Chen Z; Geng H; Zhang QC; Aghajanirefah A; Cosgun KN; Sadras T; Lee J; Mirzapoiazova T; Salgia R; Ernst T; Hochhaus A; Jumaa H; Jiang X; Weinstock DM; Graeber TG; Müschen M
Cell; 2018 Apr; 173(2):470-484.e18. PubMed ID: 29551267
[TBL] [Abstract][Full Text] [Related]
9. IKZF1
Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
[TBL] [Abstract][Full Text] [Related]
10. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
Nasr MR; Rosenthal N; Syrbu S
Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
Firtina S; Sayitoglu M; Hatirnaz O; Erbilgin Y; Oztunc C; Cinar S; Yildiz I; Celkan T; Anak S; Unuvar A; Devecioglu O; Timur C; Aydogan G; Akcay A; Atay D; Turkkan E; Karaman S; Orhaner B; Sarper N; Deniz G; Ozbek U
Leuk Res; 2012 Jan; 36(1):87-92. PubMed ID: 21813177
[TBL] [Abstract][Full Text] [Related]
13. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
[TBL] [Abstract][Full Text] [Related]
14. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
[TBL] [Abstract][Full Text] [Related]
15. Ikaros and leukaemia.
Olsson L; Johansson B
Br J Haematol; 2015 May; 169(4):479-91. PubMed ID: 25753742
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.
Isidro-Hernández M; Mayado A; Casado-García A; Martínez-Cano J; Palmi C; Fazio G; Orfao A; Ribera J; Ribera JM; Zamora L; Raboso-Gallego J; Blanco O; Alonso-López D; De Las Rivas J; Jiménez R; García Criado FJ; García Cenador MB; Ramírez-Orellana M; Cazzaniga G; Cobaleda C; Vicente-Dueñas C; Sánchez-García I
Sci Rep; 2020 Nov; 10(1):19189. PubMed ID: 33154497
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
18. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
19. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
20. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
Ofverholm I; Tran AN; Heyman M; Zachariadis V; Nordenskjöld M; Nordgren A; Barbany G
Leukemia; 2013 Sep; 27(9):1936-9. PubMed ID: 23538749
[No Abstract] [Full Text] [Related]
[Next] [New Search]
